EUCTR2007-004895-37-FR进行中（未招募）1 期
A Phase III, Randomised, Double-Blind, Dose-Response, Stratified, Placebo-Controlled Study Evaluating the Safety and Efficacy of SPD476 versus Placebo over 104 weeks in the Prevention of Recurrence of Diverticulitis.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 584
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for inclusion, each subject must meet each of the following criteria at screening, and must continue to fulfil these criteria at baseline:
- •1. Written, signed, and dated informed consent to participate in the study must be given by the subject, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before completing any study-related procedures listed in Section 6.2.
- •2. Male and female subjects ³18 years of age
- •3. Males, or non-pregnant, non-lactating females of childbearing potential (FOCP), as demonstrated by negative beta HCG (human chorionic gonadotropin) serum pregnancy test, who agree to comply with any applicable contraceptive requirements of the protocol (refer to Section 4.4)
- •4. At least one documented attack of acute diverticulitis in the previous 24 months that has clinically resolved without colonic resection. (Documentation must include: physical examination, laboratory analysis, and a verifiable report confirming acute diverticulitis by CT scan, MRI scan, or endoscopy.)
- •5. Flexible sigmoidoscopy confirmation of diverticulosis with at least three diverticula noted. Frank ulceration and evidence of ischaemia is not acceptable. The presence of mild erythema and loss of vascularity (oedema) is not exclusionary
- •6. WBC count within normal reference ranges
- •7. Polymorphonuclear leukocyte [PMN] level within normal reference ranges
- •8. Subject and Investigator must agree that participation in this study is in the best interest of the subject
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects are excluded from the study if any of the following criteria are met at screening or at baseline:
- •1. History of complicated diverticular disease (peritoneal abscesses, surgical resection for diverticular stricture, active fistula disease), history of diverticular bleed or colonic stricture
- •2. Clinically relevant gross extraluminal pathology as shown by CT scan
- •3. Right sided diverticulosis only
- •4. Abdominal pain and abdominal tenderness upon palpation
- •5. Active peptic ulcer disease
- •6. History of or current presence of inflammatory bowel disease (IBD) or documented history of irritable bowel syndrome requiring regular monthly medication
- •7. Active GI bleeding, except for positive faecal occult blood test (FOBT) in the stool
- •8. Allergy or hypersensitivity to mesalazine (5-ASA) or aspirin
- •9. Subjects with asthma are excluded only if they are known to be mesalazine-sensitive
- •10. Allergy to radiologic contrast agents
- •11. Subjects must not have used another Investigational product within 30 days prior to Baseline
- •12. Use of antibiotic therapy within 4 weeks of Baseline
- •13. Use of prebiotic medication, or probiotic medication, as well as tegaserod, alosetron, laxatives, metaclopramide, domperidone, anti-spasmotic agents, and anti-diarrhoeal agents within 14 days of Baseline
- •14. Use of biologics (anti-TNF agents)
- •15. Use of immunomodulators (e.g., azathioprine, 6-mercaptopurine) within 6 weeks prior to Baseline
- •16. Use of systemic or rectal steroids within 6 weeks of Baseline
- •17. Subjects using any anti-inflammatory drugs, including non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, COX-2 inhibitors, or ibuprofen on a regular basis (defined as over-the-counter NSAID use for 3 consecutive days or 7 occurrences per month, with the exception of aspirin [£325mg/day] taken for cardiac prophylaxis)
- •18. Subjects with clinically relevant moderate or severe renal or hepatic impairment are contraindicated with mesalazine products
- •19. Previous colorectal surgery (with the exception of haemorrhoidectomy, colonic removal of benign polyps, and appendectomy)
- •20. Current or relevant previous disease that could affect the colon, action, absorption, or disposition of the investigational product, or clinical or laboratory assessments
- •21. Malignancy, except for basal cell skin cancer, cervical carcinoma in-situ, or carcinoma in-situ in a colonoscopically removed polyp
- •22. Subjects with a history of alcohol or other substance abuse within the previous year
- •23. Current or relevant history of serious, severe, or unstable (acute of progressive) physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully complete the study, or any condition that presents undue risk from the study medication or procedures
- •24. Subjects who have previously been screened for or enrolled into this study and subsequently withdrawn
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644